Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis.

IF 2.1 4区 医学 Q3 PERIPHERAL VASCULAR DISEASE Journal of the Renin-Angiotensin-Aldosterone System Pub Date : 2021-01-01 DOI:10.1177/14703203211003781
Ying Jing, Kangla Liao, Ruolin Li, Shumin Yang, Ying Song, Wenwen He, Kanran Wang, Jun Yang, Qifu Li, Jinbo Hu
{"title":"Cardiovascular events and all-cause mortality in surgically or medically treated primary aldosteronism: A Meta-analysis.","authors":"Ying Jing,&nbsp;Kangla Liao,&nbsp;Ruolin Li,&nbsp;Shumin Yang,&nbsp;Ying Song,&nbsp;Wenwen He,&nbsp;Kanran Wang,&nbsp;Jun Yang,&nbsp;Qifu Li,&nbsp;Jinbo Hu","doi":"10.1177/14703203211003781","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To compare the effect of surgical or medical treatment on the risk of cardiovascular diseases (CVD) and all-cause mortality in patients with established primary aldosteronism (PA).</p><p><strong>Methods: </strong>We searched PUBMED, MEDLINE and Cochrane Library for the meta-analysis. We included patients who were diagnosed with PA following guideline-supported protocols and received surgery or mineralocorticoid receptor antagonist (MRA)-based medical treatment, and age-sex matched patients with treated essential hypertension (EH). Primary endpoints were CVD incidence and all-cause mortality.</p><p><strong>Results: </strong>Compared with EH, patients with treated PA had a higher risk of CVD [odds ratio (OR) 1.79; 95% confidence interval (CI) 1.39-2.31]. This elevated risk was only observed in patients with medically treated PA [OR 2.11; 95%CI 1.88-2.38] but not in those with surgically treated PA. The risk of all-cause mortality was significantly lower in patients with treated PA [OR 0.86; 95% CI 0.77-0.95] compared to EH. The reduced risk was only observed in patients with surgically treated PA [OR 0.47; 95% CI 0.34-0.66], but not in those with medically treated PA.</p><p><strong>Conclusions: </strong>Patients with medically treated PA have a higher risk of CVD compared to patients with EH. Surgical treatment of PA reduces the risk of CVD and all-cause mortality in patients with PA.</p>","PeriodicalId":17330,"journal":{"name":"Journal of the Renin-Angiotensin-Aldosterone System","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/14703203211003781","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Renin-Angiotensin-Aldosterone System","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14703203211003781","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 8

Abstract

Objectives: To compare the effect of surgical or medical treatment on the risk of cardiovascular diseases (CVD) and all-cause mortality in patients with established primary aldosteronism (PA).

Methods: We searched PUBMED, MEDLINE and Cochrane Library for the meta-analysis. We included patients who were diagnosed with PA following guideline-supported protocols and received surgery or mineralocorticoid receptor antagonist (MRA)-based medical treatment, and age-sex matched patients with treated essential hypertension (EH). Primary endpoints were CVD incidence and all-cause mortality.

Results: Compared with EH, patients with treated PA had a higher risk of CVD [odds ratio (OR) 1.79; 95% confidence interval (CI) 1.39-2.31]. This elevated risk was only observed in patients with medically treated PA [OR 2.11; 95%CI 1.88-2.38] but not in those with surgically treated PA. The risk of all-cause mortality was significantly lower in patients with treated PA [OR 0.86; 95% CI 0.77-0.95] compared to EH. The reduced risk was only observed in patients with surgically treated PA [OR 0.47; 95% CI 0.34-0.66], but not in those with medically treated PA.

Conclusions: Patients with medically treated PA have a higher risk of CVD compared to patients with EH. Surgical treatment of PA reduces the risk of CVD and all-cause mortality in patients with PA.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
手术或药物治疗原发性醛固酮增多症的心血管事件和全因死亡率:一项荟萃分析
目的:比较手术或药物治疗对原发性醛固酮增多症(PA)患者心血管疾病(CVD)风险和全因死亡率的影响。方法:检索PUBMED、MEDLINE和Cochrane图书馆进行meta分析。我们纳入了遵循指南支持方案诊断为PA并接受手术或矿皮质激素受体拮抗剂(MRA)药物治疗的患者,以及年龄性别匹配的治疗过的原发性高血压(EH)患者。主要终点是心血管疾病发病率和全因死亡率。结果:与EH相比,经治疗的PA患者发生CVD的风险更高[优势比(OR) 1.79;95%置信区间(CI) 1.39-2.31]。这种升高的风险仅在接受药物治疗的PA患者中观察到[OR 2.11;95%CI 1.88-2.38],但手术治疗的PA患者无此症状。经治疗的PA患者全因死亡风险显著降低[OR 0.86;95% CI 0.77-0.95]。仅在手术治疗的PA患者中观察到风险降低[OR 0.47;95% CI 0.34-0.66],但在接受药物治疗的PA患者中没有。结论:与EH患者相比,经药物治疗的PA患者发生心血管疾病的风险更高。前列腺癌的手术治疗降低了心血管疾病和全因死亡率的风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
16
审稿时长
6-12 weeks
期刊介绍: JRAAS is a peer-reviewed, open access journal, serving as a resource for biomedical professionals, primarily with an active interest in the renin-angiotensin-aldosterone system in humans and other mammals. It publishes original research and reviews on the normal and abnormal function of this system and its pharmacology and therapeutics, mostly in a cardiovascular context but including research in all areas where this system is present, including the brain, lungs and gastro-intestinal tract.
期刊最新文献
Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and the Risk of COVID-19: A Meta-Analysis. Genetic Variants Associated with High Susceptibility of Premature Ischemic Stroke. Timing Matters: Effects of Early and Late Estrogen Replacement Therapy on Glucose Metabolism and Vascular Reactivity in Ovariectomized Aged Wistar Rats. Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic. New Viral Diseases and New Possible Remedies by Means of the Pharmacology of the Renin-Angiotensin System.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1